NanoString Technologies (NSTG) Launches Translational Research Assays Under Vantage 3D Product Line
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/25/2024
- Futures falter as Meta Platforms weighs on megacaps
- Meta shares dip on softer Q2 revenue guidance, elevated AI spending plans
- Oil steady as US demand concerns balance Middle East conflict risks
- Yen at multi-decade lows, dollar drops before US data
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Hasbro (HAS) brand strength sees earnings top expectations
- Meta Platforms (META) Tops Q1 EPS by 39c, Offers Guidance
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- Crude Inventory Declined 6.4 Million Barrels Last Week
- After-hours movers: Meta, Ford, IBM, ServiceNow and more
- Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
NanoString Enhances Solid Tumor Profiling with 3D Biology Capabilities for Formalin-Fixed, Paraffin-Embedded (FFPE) Tissue Samples
October 18, 2016 6:03 AM EDTSEATTLE, Oct. 18, 2016 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (NASDAQ: NSTG), a provider of life science tools for translational research and molecular diagnostic products, today announced the commercial launch of two new translational research assays in the companys Vantage 3D product line at the American Society of Human Genetics (ASHG) Annual Meeting in Vancouver Canada:
nCounter Vantage 3D DNA (SNV) Solid Tumor PanelnCounter Vantage 3D Protein Solid Tumor Signaling Pathways PanelThe two new panels can be combined with one another as well as with the... More
